A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

Completed · Phase 1

Conditions studied: Carcinoma, Hepatocellular

In brief

Liver cancer is a good target for anti-angiogenic treatments such as pazopanib. The effect of pazopanib in patients with liver cancer are unknown. This study is designed to evaluate the safety, tolerability and best dose of pazopanib to be given to patient with liver cancer.

Key facts

Study ID

NCT00370513

Run by

GlaxoSmithKline

People needed

28

Starts

2006-12-06

Expected to finish

2009-04-08

Last updated by the study team

2017-11-17

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of advanced liver cancer adequate bone marrow, liver and kidney function
• Any local therapy for tumor must have been completed at least 4 weeks prior to enrolling in study

You may not qualify if…

• Pregnant or breastfeeding
• Any serious or unstable medical or psychiatric conditions
• History of metastases to central nervous system
• History of ulcer, inflammatory bowel disease or disease of the gut
• History of HIV, or uncontrolled infection
• Have had a cardiac condition or stoke during the past 6 months
• High blood pressure
• Have had a blood clot during the past 6 months
• History of bleeding blood vessels

Where it is running

• GSK Investigational Site — San Francisco, California, United States
• GSK Investigational Site — Hong Kong, Hong Kong
• GSK Investigational Site — Taipei, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.